Pfizer (PFE) executive says obesity study results increase significantly Co's confidence in Phase 3 monthly dosing study set to launch this year; targeting the first of a series of potential obesity approvals in 2028

Pfizer's announcement regarding increased confidence in their obesity study suggests a promising outlook for their Phase 3 trial, indicative of potential positive revenue streams in the future.

Newsquawk StaffPublished On the live feed at 10 more headlines followed before this page went public
Newsquawk headlinesUTC

AMETEK Inc. (AME) Q4 2025 (USD): Basic EPS 1.74 (exp. 1.94), Revenue 1.998bln (exp. 1.95bln)

US envoy Witkoff arrives in Israel

Pfizer (PFE) executive says obesity study results increase significantly Co's confidence in Phase 3 monthly dosing study set to launch this year; targeting the first of a series of potential obesity approvals in 2028

Pfizer Inc. (PFE) Q4 2025 (USD): Adj. EPS 0.66 (exp. 0.58), Revenue 17.6bln (exp. 16.85bln); FY26 revenue view 59.5-62.5bln (exp. 61.94bln), FY26 EPS 2.80-3.00 (exp. 2.97)

Ukraine's President Zelensky calls for additional support following discussion with NATO's Rutte

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

This could heavily influence investor sentiment, as the market often responds favorably to strong clinical trial news, especially when tied to large target markets like obesity management. Traders should monitor how this information impacts Pfizer's stock trajectory and the broader pharmaceutical sector, particularly as upcoming trials and approvals unfold.

Related headlines

The whole workspace, free to try.

Try it free